Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial

Overview

This is a pilot trial to discover the feasibility of recruiting 50 pts over the course of 12 months. The trial is testing the efficacy of using cold-stored vs. room temperature stored (current standard of care) platelets to treat bleeding in persons with hematological disorders and thrombocytopenia.

Detailed description

Patients with hematologic malignancies or marrow aplasia are at increased risk of bleeding. While prophylactic platelet transfusions reduce the risk of bleeding compared with no prophylaxis, a significant risk of bleeding remains, with 43-54% of patients with a hematologic malignancy or marrow aplasia receiving chemotherapy, immunotherapy, or hematopoietic stem cell transplant (HSCT) experiencing WHO grade 2 or higher bleeding \[Stanworth et al. NEJM 2013; Gernsheimer et al, Blood 2020\]. Improved efficacy of therapeutic platelet transfusions would benefit this patient population. In vitro data suggests that cold-stored platelets have greater hemostatic responsiveness than those stored at room temperature.

This study will evaluate the feasibility of a randomized clinical trial comparing cold- and room temperature storage in patients admitted to hospital with a hematologic malignancy or marrow aplasia. Results will inform estimates of transfusion requirements and changes in bleeding severity for power calculations, inform management of a cold-stored platelet inventory, and will provide data on the use of cold-stored platelets in the Canadian health-care setting.

Interventions

• Biological Cold-stored platelet concentrate
  Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C

Primary outcome measures

• Average Enrollment [Time frame: 12 months]
• Enrollment Achieved [Time frame: 12 months]

Secondary outcome measures (5)

• Eligible patients consented [Time frame: 12 months]
• Non-participation [Time frame: 12 months]
• Protocol Adherance [Time frame: 12 months]
• Withdrawal/ Loss to follow up [Time frame: 12 months]
• Expired Cold-platelets [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

• Adult patients (age ≥ 18) admitted to Malignant Hematology ward with hematologic malignancy or marrow aplasia, this may include patients undergoing chemotherapy, immunotherapy, or hematopoietic stem cell transplant or patients admitted for symptom management.
• Moderate thrombocytopenia, platelet concentration 10-100 x109/L
• Platelet transfusion ordered to treat bleeding

Exclusion criteria

• Severe thrombocytopenia (platelet concentration <10 x 109/L)
• Known platelet refractoriness requiring HLA or HPA selected platelet concentrates
• International normalized ratio (INR) >2.0
• Activated partial thromboplastin time (aPTT) >40 seconds
• Therapeutic anticoagulation (unfractionated heparin, low molecular weight heparin, warfarin, direct oral anticoagulant)
• Known congenital bleeding disorder
• History of unprovoked venous thromboembolic disease
• Transfusion of platelet concentrate for >grade 2 bleeding in preceding 24 hours
• Order for multiple platelet transfusion at once
• Refusal of blood transfusion
• Prior participation in CoVeRTS-HM trial
• Participation in other clinical trials with interventions that may affect CoVeRTS-HM treatment or outcome
• Unable or unwilling to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Single group

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

Canada · 1 center

• The Ottawa Hospital - General Campus — Ottawa

Identifiers

NCT: NCT05820126 · CoVeRTS-HM

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗